Akari Therapeutics Plc ADR

AKTXNASDAQ · USD
9.81USD0.00 (+0.57%)
212

Akari Therapeutics Plc ADR (AKTX) Covered Calls

As of September 25, 2026, AKTX has 10 covered call opportunities in the coming three months. Return ranges from 4.5 to 83.9% until expiration. Annualized return ranges from 38.5 to 196.3%. The nearest expiration is October 16, 2026. Maximum potential profit is $819.

Read more

Running AKTX covered calls helps you generate consistent income from Akari Therapeutics Plc ADR's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Akari Therapeutics Plc ADR involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best AKTX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if AKTX stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling AKTX covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Akari Therapeutics Plc ADR covered call is worth writing.

Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nomacopan holds promise for a range of serious conditions, including paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). Akari's operations are headquartered in London, United Kingdom.

Income-focused investors, long-term AKTX holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling AKTX covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Akari Therapeutics Plc ADR covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile—
  • Market cap (M$)17
  • 52 weeks high-77.91%
  • 52 weeks low224.83%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$25.50
    159.94% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-12-04
  • P/E—
  • Future P/E—
  • EPS (ttm)-17.25
  • EPS growth next 5 years46.65%

As of September 25, 2026

2026-11-205612.5028.070.204.00294.0030.12196.34-2.05+0.5203.80
2027-01-1511215.0053.690.204.50544.0055.74181.65-2.05+0.5104.30
2027-04-1620317.5079.300.455.50819.0083.91150.88-4.61+0.5505.05
2027-04-1620315.0053.690.855.10609.0062.40112.19-8.71+0.5704.25
2027-01-1511212.5028.070.454.20319.0032.68106.52-4.61+0.5503.75
2026-10-162110.002.460.203.1044.004.5178.36-2.05+0.5702.90
2027-04-1620312.5028.071.355.60409.0041.9175.35-13.83+0.6404.25
2026-11-205610.002.460.654.1089.009.1259.44-6.66+0.6103.45
2027-01-1511210.002.461.204.90144.0014.7548.08-12.30+0.6503.70
2027-04-1620310.002.461.856.20209.0021.4138.50-18.95+0.7114.35

As of September 25, 2026

Sell covered calls with the data behind you

Find the best AKTX covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial